Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AGEN2373 |
Synonyms | |
Therapy Description |
AGEN2373 is a antibody that targets CD137 and acts as an agonist, resulting in increased CD137 signaling and potentially leading to enhanced anti-tumor immune response (Journal of Clinical Oncology 2019 37:15_suppl, e14005). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AGEN2373 | AGEN-2373|AGEN 2373 | TNFRSF9 Antibody 32 | AGEN2373 is a antibody that targets CD137 and acts as an agonist, resulting in increased CD137 signaling and potentially leading to enhanced anti-tumor immune response (Journal of Clinical Oncology 2019 37:15_suppl, e14005). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04121676 | Phase I | AGEN2373 | A Study in Subjects With Advanced Cancer | Completed | USA | 0 |